{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:02:41Z","timestamp":1746417761215,"version":"3.40.4"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002865","name":"Chongqing Science and Technology Commission","doi-asserted-by":"crossref","award":["cstc2017shmsA130105"],"award-info":[{"award-number":["cstc2017shmsA130105"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chongqing Wanzhou Science and Technology Commission","award":["wzstc-2017002"],"award-info":[{"award-number":["wzstc-2017002"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The objective of this study is to systematically evaluate the efficacy and safety of the calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant for the treatment of acute migraine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Randomized controlled trials (RCTs) of ubrogepant for treatment of acute migraine were identified in PubMed, MEDLINE, EMBASE, and the Cochrane Library from database establishment to June 2020; we also searched ClinicalTrials.gov manually during the same period. Then, RevMan 5.3 software was used to perform a meta-analysis on each outcome measure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 5 RCTs involving 4903 patients were included; there were 3358 cases in the ubrogepant group and 1545 cases in the placebo group. The meta-analysis showed the following results: at 2\u200ahours postdose, the percentages of participants reporting pain relief and the absence of photophobia, nausea, and phonophobia were significantly higher in the ubrogepant group than in the placebo group (odds ratio [OR]\u200a=\u200a1.71, 95%CI: 1.48\u20131.97, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.00001; OR\u200a=\u200a1.33, 95%CI: 1.22\u20131.45, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.00001; OR\u200a=\u200a1.07, 95%CI: 1.03\u20131.11, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.0006; OR\u200a=\u200a1.21, 95%CI: 1.14\u20131.28, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.00001). The incidence of common adverse events was similar between the 2 groups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&gt;\u200a.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Ubrogepant is effective and safe for the treatment of acute migraine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Registration number:<\/jats:title>\n            <jats:p>PROSPERO CRD42019145286.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000024741","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T01:02:08Z","timestamp":1614906128000},"page":"e24741","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine"],"prefix":"10.1097","volume":"100","author":[{"given":"Zizhen","family":"Zhang","sequence":"first","affiliation":[{"name":"School of Pharmacy, Southwest Medical University, Luzhou Sichuan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Shu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Southwest Medical University, Luzhou Sichuan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Diao","sequence":"additional","affiliation":[{"name":"School of Pharmacy, North Sichuan Medical College, Nanchong Sichuan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Psychosomatic Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhi","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Southwest Medical University, Luzhou Sichuan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, North Sichuan Medical College, Nanchong Sichuan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1439-726X","authenticated-orcid":false,"given":"Biao","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Affiliated Three Gorges Hospital of Chongqing University, Chongqing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"J Physiol Rev"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1468-2982.2005.01026.x","article-title":"The postdrome of the acute migraine attack","volume":"26","author":"Kelman","year":"2006","journal-title":"J Cephalalgia"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1526-4610.2005.05159.x","article-title":"Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs","volume":"45","author":"Kelman","year":"2005","journal-title":"J Headache"},{"key":"R4-20250504","first-page":"119","article-title":"Preferential occurrence of attacks during night sleep and\/or upon awakening negatively affects migraine clinical presentation","volume":"30","author":"Gori","year":"2015","journal-title":"J Funct Neurol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","year":"2017","journal-title":"Lancet Neurol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMra1915327","article-title":"Migraine","volume":"383","author":"Ashina","year":"2020","journal-title":"N Engl J Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dmcn.14338","article-title":"Episodic and chronic migraine in children","volume":"62","author":"Youssef","year":"2020","journal-title":"Dev Med Child Neurol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/13543784.2019.1618830","article-title":"Gepants for the treatment of migraine","volume":"28","author":"Negro","year":"2019","journal-title":"J Expert Opin Investig Drugs"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","article-title":"Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine","volume":"44","author":"Dodick","year":"2004","journal-title":"J Headache"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10194-011-0388-3","article-title":"Chronic migraine plus medication overuse headache: two entities or not?","volume":"12","author":"Negro","year":"2011","journal-title":"J Headache Pain"},{"key":"R11-20250504","first-page":"367","article-title":"Meta analysis of the efficacy and safety of galcanezumab in the prophylactic treatment of migraine","volume":"38","author":"Zhang","year":"2019","journal-title":"J Chin J New Drugs Clin Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2005.11.020","article-title":"Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity","volume":"530","author":"Gupta","year":"2006","journal-title":"J Eur J Pharmacol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.npep.2010.12.002","article-title":"Calcitonin gene-related peptide (CGRP) and its role in hypertension","volume":"45","author":"Smillie","year":"2011","journal-title":"J Neuropeptides"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-019-00665-9","article-title":"Recent advances in pharmacotherapy for episodic migrain","volume":"33","author":"Chan","year":"2019","journal-title":"J CNS Drugs"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/0333102416653233","article-title":"A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine","volume":"36","author":"Voss","year":"2016","journal-title":"J Cephalalgia"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"J N Engl J Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1177\/0333102419869918","article-title":"Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: randomized, placebo-controlled trial in healthy adults","volume":"39","author":"Goadsby","year":"2019","journal-title":"J Cephalalgia"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s10194-019-0974-3","article-title":"Therapeutic novelties in migraine: new drugs, new hope?","volume":"20","author":"Do","year":"2019","journal-title":"J Headache Pain"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:09:08Z","timestamp":1746338948000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024741"}},"subtitle":["A meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024741","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"assertion":[{"value":"2020-09-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}